National Collaborating Centre for Mental Health. Psychosis and Schizophrenia in Adults: Treatment and Management.
Clinical Guideline 178. NICE, 2014.
Meltzer, HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opinion
1997; 14: 1–20.
Meltzer, HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull
1992; 18: 51–42.
Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med
1993; 329: 162–7.
Dunk, LR, Annan, LJ, Andrews, CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry
2006; 188: 255–63.
Rostami-Hodjegan, A, Amin, AM, Spencer, EP, Lennard, MS, Tucker, GT, Flanagan, RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol
2004; 24: 70–8.
Taylor, D, Paton, C, Kapur, S. The Maudsley Prescribing Guidelines in Psychiatry.
12th edn. Wiley Blackwell, 2015.
Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res
2012; 134: 180–6.
Meyer, N, Gee, S, Whiskey, E, Taylor, D, Mijovic, A, Gaughran, F, et al. Optimizing outcomes in clozapine rechallenge following neuttropenia: a cohort analysis. J Clin Psychiatry
2015; 76: 1410–6.
Correll, CU, Gallego, JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am
2012; 35: 661–81.
Mintzer, DM, Billet, SN, Chmielewski, L. Drug-induced hematologic syndromes. Adv Hematol
2009; 2009: 495863.
Murphy, DL, Goodwin, FK, Bunney, WE Jr. Leukocytosis during lithium treatment. Am J Psychiatry
1971; 127: 1559–61.
Tisman, G, Herbert, V, Rosenblatt, S. Evidence that lithium induces human granulocyte proliferation: elevated serum vitamin B12 binding capacity in vivo and granulocyte colony proliferation in vitro. Br J Haematol
1973; 24: 767–71.
Blier, P, Slater, S, Measham, T, Koch, M, Wiviott, G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol
1998; 13: 137–40.
Whiskey, E, Taylor, D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs
2007; 21: 25–35.
Goldstein, JI, Jarskog, LF, Hilliard, C, Alfirevic, A, Duncan, L, Fourches, D, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun
2014; 5: 4757.
Pereira, A, Dean, B. Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem Pharmacol
2006; 72: 783–93.
Duggal, HS, Singh, I. Psychotropic drug-induced neutropenia. Drugs Today
2005; 41: 517–26.
Fehsel, K, Loeffler, S, Krieger, K, Henning, U, Agelink, M, Kolb-Bachofen, V, et al. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol
2005; 25: 419–26.
R⊘ge, R, M⊘ller, BK, Andersen, CR, Correll, CU, Nielsen, J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?
2012; 140: 204–13.
Haddy, TB, Rana, SR, Castro, O. Benign ethnic neutropenia: what is a normal absolute neutrophil count?
J Lab Clin Med
1999; 133: 15–22.
Flanagan, RJ, Dunk, L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol
2008; 23 (Suppl 1): 27–41.